ROS overproduction induced by LPS treatment was remarkably reduced by NBP2–29328, an inhibitor of MyD88, providing direct evidence that TLR-4 activation is connected with ROS production in LPS-treated C6 glioma cells. This evidence concerns the gene MYD88 and central nervous system cancer.